Annexin A2 Regulates AKT Upon H₂O₂-Dependent Signaling Activation in Cancer Cells.

ANXA2 H2O2-dependent signaling PI3K/AKT PRDX2 PTEN

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
07 Apr 2019
Historique:
received: 14 03 2019
revised: 31 03 2019
accepted: 03 04 2019
entrez: 10 4 2019
pubmed: 10 4 2019
medline: 10 4 2019
Statut: epublish

Résumé

Hydrogen peroxide (H₂O₂) is a main second messenger in oncogenic signaling networks including the Ras and the growth factor receptor pathways. This is achieved predominantly through the oxidation of redox-sensitive cysteine (Cys) residues in proteins resulting in changes to their structure and function. We previously identified annexin A2 (ANXA2) as a redox regulatory protein that plays an important cellular role during oxidative stress and also promoting tumorigenesis. Here we investigated the role of ANXA2 in the regulation of H₂O₂-dependent signaling that drives tumor progression. We show that depletion of ANXA2 leads to the enhanced activation of AKT following either EGF/EGFR stimulation or oncogenic Ras transformation. The phosphatase and tensin homologue (PTEN) protein negatively regulates the PI3K/AKT pathway. We demonstrate that ANXA2 via its reactive Cys-8 residue, binds to PTEN and that the co-expression of PTEN and ANXA2, but not ANXA2 Cys-8-Ala mutant, inhibits AKT phosphorylation on Ser 473. These results indicate that ANXA2 is important for PTEN regulation within the PI3K/AKT signaling cascade. Furthermore, we also reveal that ANXA2 inversely regulates the expression of the peroxidase, peroxiredoxin 2, in a reactive oxygen species dependent manner.

Identifiants

pubmed: 30959964
pii: cancers11040492
doi: 10.3390/cancers11040492
pmc: PMC6520733
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Foundation for Science and Technology (FCT), Portugal
ID : IF/00614/2014
Organisme : Foundation for Science and Technology (FCT), Portugal
ID : IF/00614/2014/CP12340006
Organisme : Foundation for Science and Technology (FCT), Portugal
ID : UID/BIM/04773/2013CBMR1334
Organisme : Foundation for Science and Technology (FCT), Portugal
ID : WELCOMEII/57/UALG/1050/2011
Organisme : ERASMUS Mundus fellowship (EMQAL)
ID : FPAnr2013-0225
Organisme : Ollie Young Foundation
ID : 1148511

Références

EMBO J. 2000 Jun 1;19(11):2393-8
pubmed: 10835338
J Cell Biol. 2000 Sep 4;150(5):1113-24
pubmed: 10973999
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
EMBO J. 1983;2(3):309-15
pubmed: 11894943
Physiol Rev. 2002 Apr;82(2):331-71
pubmed: 11917092
Trends Cell Biol. 2003 Jan;13(1):43-50
pubmed: 12480339
Science. 2003 Apr 25;300(5619):650-3
pubmed: 12714747
J Biol Chem. 1992 Oct 25;267(30):21839-43
pubmed: 1400494
EMBO J. 2003 Oct 15;22(20):5501-10
pubmed: 14532122
Mol Syst Biol. 2005;1:2005.0010
pubmed: 16729045
Science. 2006 Jun 30;312(5782):1882-3
pubmed: 16809515
Mol Cell. 2007 Apr 13;26(1):1-14
pubmed: 17434122
Nat Rev Mol Cell Biol. 2008 Jul;9(7):517-31
pubmed: 18568040
J Biol Chem. 1991 Oct 5;266(28):18964-8
pubmed: 1918011
EMBO J. 2009 May 20;28(10):1505-17
pubmed: 19369943
Free Radic Res. 2010 May;44(5):479-96
pubmed: 20370557
Acta Biochim Pol. 2010;57(2):179-83
pubmed: 20512167
Oxid Med Cell Longev. 2010 Jan-Feb;3(1):23-34
pubmed: 20716925
Antioxid Redox Signal. 2011 Aug 1;15(3):781-94
pubmed: 20919930
J Biol Chem. 2011 Mar 11;286(10):8394-404
pubmed: 21148313
J Biol Chem. 1990 May 15;265(14):7709-12
pubmed: 2186024
Blood. 2011 Nov 3;118(18):4789-97
pubmed: 21908427
Oncotarget. 2011 Dec;2(12):1075-93
pubmed: 22185818
Cell Signal. 2012 May;24(5):981-90
pubmed: 22286106
Blood. 2012 Oct 25;120(17):3397-406
pubmed: 22898602
Biochem Biophys Res Commun. 1990 Jan 15;166(1):146-53
pubmed: 2302198
J Biomed Biotechnol. 2012;2012:353687
pubmed: 23118506
PLoS One. 2012;7(11):e50591
pubmed: 23226323
Int J Mol Sci. 2013 Feb 07;14(2):3568-94
pubmed: 23434659
Oxid Med Cell Longev. 2016;2016:8413032
pubmed: 26682014

Auteurs

Stéphanie Anais Castaldo (SA)

Centre for Biomedical Research (CBMR), Campus of Gambelas, University of Algarve, Building 8, Room 2.22, 8005-139 Faro, Portugal. stephanie.castaldo@cme.vib-kuleuven.be.

Tom Ajime (T)

Centre for Biomedical Research (CBMR), Campus of Gambelas, University of Algarve, Building 8, Room 2.22, 8005-139 Faro, Portugal. tommysawyer2002@gmail.com.

Gisela Serrão (G)

Centre for Biomedical Research (CBMR), Campus of Gambelas, University of Algarve, Building 8, Room 2.22, 8005-139 Faro, Portugal. giselaserrao@gmail.com.

Fábio Anastácio (F)

Centre for Biomedical Research (CBMR), Campus of Gambelas, University of Algarve, Building 8, Room 2.22, 8005-139 Faro, Portugal. fabioanastacio@live.com.pt.

Joana Teixeira Rosa (JT)

Centre for Biomedical Research (CBMR), Campus of Gambelas, University of Algarve, Building 8, Room 2.22, 8005-139 Faro, Portugal. joana.t.rosa@gmail.com.

Carman Anthony Giacomantonio (CA)

Department of Medicine, Dalhousie University, Halifax, Nova Scotia B3H 4R2, Canada. carman.giacomantonio@dal.ca.

Alison Howarth (A)

Brain Tumour Research Centre of Excellence, Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, PO1 2DT Portsmouth, UK. alison.howarth@port.ac.uk.

Richard Hill (R)

Centre for Biomedical Research (CBMR), Campus of Gambelas, University of Algarve, Building 8, Room 2.22, 8005-139 Faro, Portugal. richard.hill@port.ac.uk.
Brain Tumour Research Centre of Excellence, Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, PO1 2DT Portsmouth, UK. richard.hill@port.ac.uk.

Patrícia Alexandra Madureira (PA)

Centre for Biomedical Research (CBMR), Campus of Gambelas, University of Algarve, Building 8, Room 2.22, 8005-139 Faro, Portugal. pamadureira@ualg.pt.
Brain Tumour Research Centre of Excellence, Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, PO1 2DT Portsmouth, UK. pamadureira@ualg.pt.

Classifications MeSH